Your browser doesn't support javascript.
loading
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
Giralt, Sergio; Jolles, Stephen; Kerre, Tessa; Lazarus, Hillard M; Mustafa, S Shahzad; Papanicolaou, Genovefa A; Ria, Roberto; Vinh, Donald C; Wingard, John R.
Afiliação
  • Giralt S; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address: GiraltS@mskcc.org.
  • Jolles S; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.
  • Kerre T; Department of Hematology, Ghent University Hospital, Ghent, Belgium.
  • Lazarus HM; Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH, United States.
  • Mustafa SS; Rochester Regional Health, Rochester, NY, United States; University of Rochester School of Medicine & Dentistry, Rochester, NY, United States.
  • Papanicolaou GA; Department of Medicine, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Ria R; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro Medical School, Bari, Italy.
  • Vinh DC; Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
  • Wingard JR; Department of Medicine, Division of Hematology Oncology, University of Florida, Gainesville, FL, United States.
Clin Lymphoma Myeloma Leuk ; 23(10): 719-732, 2023 10.
Article em En | MEDLINE | ID: mdl-37353432
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agamaglobulinemia / Síndromes de Imunodeficiência / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agamaglobulinemia / Síndromes de Imunodeficiência / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article